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Abstract 
Background: Volume resuscitation with hydroxyethyl starch (HES) is controversially discussed and we recently 
showed that HES perfusion impairs endothelial and epithelial intestinal barrier integrity. Here we investigated whether 
Albumin containing HES solutions are superior to HES alone in maintaining intestinal barrier function.
Methods: An isolated perfused model of the mouse small intestine was used to investigate the effects of: (i) 3 % 
Albumin (Alb), (ii) 3 % HES or (iii) 1.5 % HES/1.5 % Albumin (HES/Alb). Intestinal morphology, cell damage, metabolic 
functions, fluid shifts and endothelial/epithelial barrier permeability were evaluated. Potentially involved signaling 
mechanisms (Erk1/2, Akt and Stat5 phosphorylation) were screened.
Results: HES induced histomorphological damage (p < 0.01 vs. Alb), by trend elevated the amount of luminal 
intestinal fatty acid binding protein and reduced galactose uptake (p < 0.001 vs. Alb). Luminal and lymphatic flow 
rates were increased (p < 0.001 vs. Alb), while vascular flow was decreased (p < 0.001 vs. Alb) during HES perfusion. 
HES also increased the vascular to luminal FITC-dextran transfer (p < 0.001 vs. Alb), pointing towards a fluid shift from 
the vascular to the luminal and lymphatic compartments during HES perfusion. Addition of Alb (HES/Alb) reversed all 
adverse effects of HES (p < 0.05 vs. HES), restored barrier integrity (p < 0.05 vs. HES) and improved metabolic function 
of the intestine (p < 0.001 vs. HES; p < 0.05 vs. Alb). Mechanistically, HES/Alb perfusion resulted in an increased phos-
phorylation of Erk1/2 and Akt kinases (p < 0.001 vs. HES), while Stat5 remained unchanged.
Conclusions: Albumin supplementation abrogates the adverse effects of HES in the intestine and underlying 
mechanism may function via phosphorylation of Erk1/2 and Akt. Albumin containing HES solutions are superior to 
HES alone and may improve the suitability of HES in the clinic.
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Background
Hypovolemia due to hemorrhage, burns, trauma, and 
dehydration either alone or in combination requires fluid 
therapy to restore vascular volume and normalize venous 
return, cardiac output and blood pressure. Therefore, 
the common clinical treatment for patients with hypov-
olemia is a fluid resuscitation using crystalloid or colloi-
dal solutions [1, 2].
Beside human Albumin (Alb), hydroxyethyl starch 
(HES) a synthetic nonionic starch derivate available in 
different molecular weight and substitution forms, is one 
of the most effective and commonly used colloids in Can-
ada, China, New Zealand, Switzerland and other non-
European countries [1, 3]. However, based on several 
recently published studies that suggest a higher risk for 
renal replacement therapy and increased mortality after 
fluid resuscitation with HES [1, 4], the European Medi-
cines Agency’s (EMA) Pharmacovigilance Risk Assess-
ment Committee instructed that HES solutions must no 
longer be used to treat patients with sepsis, burn injuries 
or critically ill patients (EMA/606303/2013). Despite the 
EMA recommendation, HES is still used for the treat-
ment of hypovolemia in various clinical settings through-
out Europe and other countries.
Information about the HES mediated physiological and 
cellular mechanisms that are responsible for the adverse 
effects of HES in specific organs is very scarce and has 
mainly been described in the heart [5] and kidney [6]. 
Unexpectedly, animal studies even showed positive 
effects of HES on inflammatory processes during sepsis 
[7–10] and concerning the negative effects of HES solu-
tions on vascular permeability in the heart, some studies 
suggested that addition of Alb to HES containing solu-
tions might be beneficial and could have the potential 
to reduce the adverse effects of HES [5, 11]. A deeper 
understanding of the HES mediated mechanisms is 
therefore necessary and could help to reduce the adverse 
effects and augment the positive influence of HES in the 
affected organs under different clinical situations.
Endothelial and epithelial damage/dysfunction is a 
prerequisite for hypovolemia in most clinical settings. 
Therefore, in hypovolemia, fluid homeostasis is highly 
dependent on the function of the intestine, which offers 
a large inner surface area serving as a selective barrier 
between the organism and the environment [12]. The 
intestinal endo- and epithelia crucially preserve the fluid 
homeostasis and barrier function between the vascular, 
interstitial and luminal compartments. Various patho-
physiological processes like inflammation or microbial 
sepsis result in an increased endothelial and epithelial 
permeability leading to edema formation as well as pas-
sage of pathogens and bacterial toxins into the systemic 
circulation [7, 8, 13–16]. Although the intestine plays a 
central role in metabolism and barrier function as well 
as in inflammation and sepsis, there are only few studies 
that have evaluated the effects of different fluid substitu-
tion strategies, specially with HES containing solutions, 
on intestinal function and barrier integrity [8, 9, 17, 18]. 
Employing an isolated perfused model of the mouse 
small intestine we have recently evaluated the intestinal 
effects of HES and showed that HES harms the intestine 
by increasing the endothelial and epithelial barrier per-
meability by so far unknown mechanisms [19].
Based on the above mentioned findings that Alb sup-
plementation may have the potential to reduce the neg-
ative effects of HES in the heart and our own data that 
show adverse effects of HES in the intestine, we hypothe-
size that addition of Alb to HES containing solutions will 
attenuate the negative effects of HES on intestinal cell 
damage, metabolic functions, fluid shifts and endothe-
lial/epithelial barrier permeability. Utilizing our perfused 
model of the small intestine we therefore evaluated histo-
morphological changes, apoptosis, I-FABP (intestinal-
fatty acid binding protein) release, galactose uptake, 
lactate-to-pyruvate ratio, wet-to-dry ratio, fluid shifts 
and luminal FITC-dextran transfer after perfusion with 
3 % Alb, 3 % HES or 1.5 % HES plus 1.5 % Alb. In addition 
phosphorylation of pro-survival kinases was investigated 
to obtain insight into the HES and Alb induced signaling 
events.
Methods
Isolated perfused mouse small intestine model
All experiments were performed with isolated small 
intestines from 7–9  weeks old C57BL/6 mice (Central 
Animal Facility UKSH, Kiel, Germany) housed with 
standard diet and water ad  libitum before surgery [19]. 
The detailed surgical procedure and ex  vivo perfusion 
has been described by our group recently [19]. Briefly, 
mice were anesthetized by inhalation of 1–3 % Sevoflu-
rane and additional intraperitoneal injection of Ketamine 
up to a maximum dose of 40 mg/kg. The small intestine 
was dissected, isolated and perfused via the aorta and the 
intestinal lumen. Perfusion was performed with constant 
flow and changes in the vascular, lymphatic and luminal 
effluent weights, perfusion pressures and buffer compo-
sitions (O2, CO2, pH, electrolytes, glucose and lactate) 
were monitored as described previously [19].
Experimental protocol
Our recently described isolated perfused mouse small 
intestine model [19] was used to evaluate the physiologi-
cal and cellular effects of a vascular perfusion with HES 
and whether the addition of Alb to the HES containing 
modified Krebs–Henseleit perfusion buffer is able to 
reduce the adverse effects of HES. The control group (Alb 
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perfusion group, Alb, N = 6) received an initial vascular 
perfusion with Alb (3 %, Sigma-Aldrich, Hamburg, Ger-
many) for 60  min (equilibration phase) followed by an 
additional 75  min of vascular perfusion with the same 
Alb containing buffer. The second group (HES perfusion 
group, HES, N = 6) received an initial vascular Alb (3 %) 
perfusion for 60  min (equilibration phase) followed by 
a perfusion with HES (3 %, 130/0.4, Fresenius Kabi, Bad 
Homburg, Germany) for 75 min. The third group (HES/
Alb perfusion group, HES/Alb, N = 6) received an initial 
vascular Alb (3  %) perfusion for 60  min (equilibration 
phase) followed by a 75 min perfusion with HES (1.5 %) 
plus Alb (1.5 %; Fig. 1). All perfusions were continuously 
applied without intermittent stops. As colloid osmotic 
pressure substantially influences fluid distribution within 
the investigated compartments (vascular, interstitial, 
luminal) only the mentioned three preparations with 
similar osmotic pressures were employed. This was also 
the reason why perfusions with 1.5 % HES alone or 1.5 % 
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Fig. 1 Experimental setting and basic components of the perfusion model. Isolated perfused mouse small intestine apparatus (a). Using a cus-
tom made, heated chamber (1) an isolated small intestine (2) is perfused (vascular system: red; luminal system: yellow) while placed on a built-in 
microbalance (3). A moveable cannulating block (4) carries the tubings, heat exchanger cannula holders (5), and bubble trap (6). Height-adjustable 
reservoirs (7, 8) allow clamping both afterloads to zero. For online analysis of fluid homeostasis all emanating liquids are quantified by use of three 
balances (9–11). Constant flow perfusion is applied by a syringe pump (12) and a roller pump (13). The vascular perfusate is prewarmed, oxygenated, 
and pH equilibrated with a tempered hollow fiber dialyzer flushed with carbogen gas (14). Pressure transducers (15–17) allow online detection of 
the luminal (yellow), venous (blue) and arterial (red) pressures. All data are recorded on a personal computer (18). To secure constant temperature, 
the chamber and cannulating block are water-jacketed and warmed by a water bath (19). The inset shows a representative photograph of a per-
fused small intestine. A arterial cannula; B venous cannula; C oral intestinal lumen cannula; D aboral intestinal lumen cannula; E lymphatic suction 
needle; modified from [21]. Experimental setting and time frame (b)
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Evaluation of morphology, fluid shifts and metabolic 
function
Details about the respective methods have been pub-
lished recently [19]. As an indicator for edema forma-
tion in the intestine, a calculation of the wet-to-dry ratio 
of the respective tissue was performed. Briefly, for the 
determination of the intestinal wet weight, a 3  cm long 
proximal portion of the small intestine without mesen-
tery and intestinal content was obtained before and after 
perfusion. The dry weight was determined after dehu-
midifying the samples for 96 h at 55  °C. Additionally, at 
the end of perfusion a 3 cm long segment of the intestine 
was fixed in 4 % formaldehyde for histological examina-
tion in which sections of intestinal tissue were stained 
with hematoxylin–eosin and periodic acid–Schiff [20]. 
Analyses of tissue damage were performed by a blinded 
investigator employing a histological stability score which 
is based on the evaluation of epithelial integrity [21] with 
the exception that only longitudinal slices were evaluated. 
To determine the endothelial and epithelial permeability 
of the intestine, 40 mg/l FITC-dextran (150 kDa; Sigma-
Aldrich, Hamburg, Germany) were added to the vascu-
lar perfusate. Samples of venous, lymphatic, and luminal 
outflow were collected every 15  min and analysed for 
the FITC-dextran content using a fluorescence ELISA 
reader (excitation 485  nm, emission 530  nm, Sunrise, 
Tecan, Crailsheim, Germany). Determination of galac-
tose resorption was performed by supplying the luminal 
perfusion buffer with 30 mM lactose. Vascular galactose 
(derived from the luminal lactose) was determined by a 
commercially available assay kit (Raffinose/D-Galactose 
Assay Kit, Megazyme, Bray, Ireland). Vascular pyruvate 
was determined in the venous outflow by an enzymatic 
photometric method (NADH method, Sigma-Aldrich, 
Hamburg, Germany). For the measurement of vascular 
lactate a blood gas analyser was employed (Gem Pre-
mier 3000, Instrumentation Laboratory, Kirchheim, 
Germany).
Determination of Caspase‑3/7 activity
Activities of the effector Caspases-3 and 7, which play 
a central role in apoptotic events were evaluated in 
intestinal tissue samples before and after perfusion 
using rhodamine based fluorometric assays (Apo-One 
homogeneous Caspase-3/7 assay, Promega Corpora-
tion, Madison, WI, USA). Treatment of the samples and 
evaluation of Caspase-3/7 activity were done on the 
basis of the manufacturer’s protocol using a fluores-
cence ELISA reader (Tecan, Crailsheim, Germany) in 
combination with the Magellan software v1.1. Protein 
extraction was performed by using RIPA buffer contain-
ing 150  mM sodium chloride, 1  % NP-40, 1  % sodium 
deoxycholate, 0.1  % sodium dodecyl sulfate (SDS) and 
50 mM Tris–HCl (pH 7.6; all from Sigma-Aldrich, Ham-
burg, Germany). The protein concentrations were deter-
mined with Roti®-Quant assays (Carl Roth, Karlsruhe, 
Germany).
Western blotting
All Western blotting experiments were performed with 
intestinal tissue samples derived before and after perfu-
sion with the exception of the I-FABP Western blot, for 
which luminal effluents were used. Protein extraction 
from intestinal tissue was performed with RIPA buffer 
containing 150  mM sodium chloride, 1  % NP-40, 0.1  % 
SDS, 1  % sodium deoxycholate, 50  mM Tris–HCl (pH 
7.6; all from Sigma-Aldrich, Hamburg, Germany) with 
protease and phosphatase inhibitors (Roche, Mannheim, 
Germany), and the protein concentrations were deter-
mined with Roti®-Quant assays (Carl Roth, Karlsruhe, 
Germany). Samples were boiled for 5 min after addition 
of SDS polyacrylamide gel electrophoresis (PAGE) sample 
buffer (62.5  mM Tris–HCl, 2  % SDS, 10  % glycerol, 5  % 
β-mercaptoethanol, all from Sigma-Aldrich, Hamburg, 
Germany). Equal amounts of protein (30  μg) or luminal 
effluents (30 µl) were separated by 10 % SDS-PAGE and 
transferred onto a PVDF membrane (Amersham Phar-
macia Biotech, Piscataway, USA). Membranes were then 
incubated in blocking solution (3 % BSA in TBS contain-
ing 0.05 % Tween 20; Sigma-Aldrich, Hamburg, Germany) 
for 1  h at room temperature, followed by an overnight 
incubation with specific antibodies against I-FABP 
(Abcam, Cambridge, UK; 1:500,000), Claudin-3 (Life 
Technologies, Darmstadt, Germany 1:1000), Erk1/2 (New 
England Biolabs, Frankfurt, Germany; 1:8000), phos-
pho-Erk1/2 (New England Biolabs; Frankfurt, Germany; 
1:8000), Akt (New England Biolabs; Frankfurt, Germany; 
1:2000), phospho-Akt (New England Biolabs; Frankfurt, 
Germany; 1:1000), Stat5 (R&D Systems, Minneapolis, 
MN, USA; 1:1000) and phospho-Stat5 (R&D Systems, 
Minneapolis, MN, USA; 1:1000) or β-actin (Santa Cruz, 
Heidelberg, Germany; 1:2000) which served as a loading 
control. After washing in TBS containing 0.05  % Tween 
20 (Sigma-Aldrich, Hamburg, Germany), the membranes 
were incubated for 1 h with horseradish peroxidase conju-
gated pig anti-rabbit immunoglobulin G (Dako, Glostrup, 
Denmark; 1:10,000), rabbit anti-goat IgG-HRP (Santa 
Cruz, Heidelberg, Germany; 1:10,000) or goat anti-rabbit-
biotin (Abcam, Cambridge, UK; 1:10,000) followed by 
streptavidin-HRP (Serotec, Puchheim, Germany; 1:5000). 
The final reaction was visualized using enhanced chemi-
luminescence (ECL-Detection Reagents, GE Healthcare, 
Munich, Germany), and the membrane was exposed to 
x-ray film. Images were taken and the intensities of the 
respective bands were densitometrically analysed with the 
software ImageJ (v1.48v, NIH).
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Animal welfare and ethical statement
This study was carried out in accordance with the recom-
mendations of the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. The 
experiments were approved by the local authority (Min-
istry of Agriculture, Environment and Rural Areas of 
the State of Schleswig–Holstein, Kiel, Germany; V311-
7224.121-39). All studies involving animals are reported 
in accordance with the ARRIVE guidelines for reporting 
experiments involving animals.
Statistical analyses
Based on our recently published results [19] a power 
analysis using GraphPad StatMate 2 for Windows 
(GraphPad Software, San Diego, USA) was performed 
to estimate the numbers of animals necessary to obtain 
significant results for the primary outcome parameters 
of fluid shifts and FITC-dextran translocation. All fur-
ther statistical analyses were performed using GraphPad 
Prism 5 for Windows (GraphPad Software, San Diego, 
USA). All data sets were analysed for Gaussian distribu-
tion using the Kolmogorov–Smirnov test and -if appli-
cable- evaluated using parametric statistics. Data are 
presented as mean values with standard deviations (SD). 
Statistical comparisons were performed using Student’s 
t-tests and one-way ANOVA with Bonferroni post-
tests (for intra group comparisons) as well as two-way 
ANOVA with Bonferroni post-tests (for inter group com-
parisons). Differences were considered to be statistically 
significant if p was less than 0.05. Non-parametric data 
were analysed by Mann–Whitney-Tests, Kruskal–Wallis 
tests and Dunns post-tests.
Results
Histomorphology and cellular damage
A histological stability score [21] was modified as 
described in “Methods” section and used to evaluate the 
histomorphological damage of the intestinal epithelium. 
Perfusion with HES resulted in a significantly reduced 
histoscore compared to the Alb (p  <  0.01; Fig.  2a) or 
HES/Alb group (p < 0.01; Fig. 2a). The histomorphologi-
cal damage in the HES perfusion group was reflected by 
epithelial shedding and appearance of widened inter-
stitial spaces within the intestinal villi. These changes 
were already detectable directly at the end of perfu-
sion and could not be observed in the Alb and HES/Alb 
group (Fig. 2a). As a marker for damage of the intestinal 
epithelium, the amount of I-FABP was evaluated in the 
luminal effluents. During the first 90  min, an increased 
amount of I-FABP was detected only in the HES perfu-
sion group. However, values did not reach statistical 
significance (p > 0.05; Fig. 2b). For the quantification of 
apoptosis, a Caspase-3/7 activity assay was employed. 
The results showed increased apoptosis in intestinal tis-
sue that was obtained at the end of perfusion, but no dif-
ferences in apoptosis between the groups. These findings 
are not surprising as the ex vivo model lacks a functional 
blood circulation and nerval innervation, which are both 
important for the survival of the respective tissue and 
cells (Additional file  1: Figure  1A). In addition, in  vitro 
studies employing a commonly accepted model of intesti-
nal epithelial cells (CaCo-2) revealed that even prolonged 
incubation with high concentrations of HES (3 %) did not 
induce apoptosis or cellular damage (Additional file  1: 
Figure 1B, C), suggesting that the adverse effects of HES 
on the intestinal epithelium in the perfusion model are 
rather related to an increased interstitial pressure (edema 
formation) caused by HES molecules within the intersti-
tial compartment of the intestine and not due to HES-










































Fig. 2 Histomorphology and release of I-FABP. Quantification of 
histomorphological damage and representative histological sections 
of the perfused intestine (a). Relative amounts of I-FABP in luminal 
effluents were estimated in 15 min intervals by Western blot analyses 
(b). Bars denote the mean ± SD. Albumin (N = 6), HES (N = 6), HES/
Alb (N = 6). * p < 0.05; ** p < 0.01; scale bar 50 µm
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Basic metabolic parameters of the perfused intestine
Metabolic function of the intestine was evaluated by 
quantification of the galactose uptake (derived from 
luminal lactose) and the lactate-to-pyruvate ratio. Both 
parameters showed a time dependent decrease in all 
groups, which is related to effects of the ex  vivo per-
fusion procedure on intestinal metabolism (Fig. 3a, b). 
However, intergroup comparison revealed a signifi-
cant higher reduction of galactose uptake in the HES 
perfusion group at later time points compared to the 
Alb perfusion group (p  <  0.05 for t105; p  <  0.001 for 
t120 and t135; Fig.  3a). Interestingly, in the HES/Alb 
group the luminal galactose uptake was significantly 
increased compared to the Alb perfusion, suggesting 
positive effects of HES/Alb on metabolic functions of 
the intestine (p  <  0.05 for t135; p  <  0.01 for t90 and 
t105; Fig. 3a).
Regarding the lactate-to-pyruvate ratio, a perfusion 
related decrease was evident in all groups. There were 
no significant differences in the time response signa-
tures within or between the groups (p > 0.05, intragroup 
and intergroup comparison; Fig. 3b) and all values were 
within the physiological range of aerobic metabolism 
[22]. In addition to the described metabolic parameters, 
the wet-to-dry ratio (W/d) was calculated. In all groups, 
W/d was higher at the end of perfusion (p  <  0.001, 
Fig.  3c) and compared to a perfusion with Alb alone, 
W/d in the HES/Alb group was significantly increased 
(p < 0.01, Fig. 3c).
Effects of different colloid containing solutions on vascular, 
lymphatic and luminal flow rates
For the vascular perfusion with HES the intragroup 
comparison showed a significantly increased lymphatic 
flow rate (p < 0.01 for t90–105; p < 0.001 for t105–120 
and t120–135; Fig. 4a) and luminal flow rate (p < 0.001 
for t90–105, t105–120 and t120–135; Fig.  4b), while 
the vascular flow rate decreased (p < 0.001 for t90–105, 
t105–120 and t120–135; Fig.  4c). Vascular, lymphatic 
and luminal flow rates did not show any statistically 
significant changes over time in the Alb and HES/Alb 
group (intragroup comparison, p  >  0.05; Fig.  4a–c). 
Intergroup comparison (vs. the Alb group) revealed 
that HES perfusion significantly increased lymphatic 
flow (p < 0.05 for t75–90; p < 0.001 for t90–105, t105–
120 and t120–135; Fig. 4a) and luminal flow (p < 0.01 
for t75–90; p < 0.001 for t90–105, t105–120 and t120–
135; Fig. 4b), while vascular flow was reduced (p < 0.01 
for t105–120; p < 0.001 for t120–135; Fig. 4c) suggest-
ing that HES perfusion impairs endothelial and epithe-
lial barrier integrity, resulting in fluid shifts towards 
the lymphatic and luminal compartment. Replacing 
1.5 % HES by 1.5 % Alb abrogated all negative effects of 
HES on lymphatic flow (p < 0.05 for t75–90; p < 0.001 
for t90–105, t105–120 and t120–135; Fig. 4a), luminal 
flow (p < 0.01 for t75–90; p < 0.001 for t90–105, t105–
120 and t120–135; Fig. 4b) and vascular flow (p < 0.01 
for t90–105; p  <  0.001 for t105–120 and t120–135; 
Fig.  4c). No statistically significant differences were 
detected between the Alb and HES/Alb group con-
cerning lymphatic, luminal and vascular flow (p > 0.05; 
Fig. 4a–c).













































































Fig. 3 Metabolic parameters of the perfused intestine. The relative 
luminal galactose uptake was measured by a galactose assay kit (a), 
the lactate-to-pyruvate ratio was evaluated by blood gas analysis 
and an enzymatic photometric method (b), and the wet-to-dry ratio 
before (W/d1) as well as after (W/d2) perfusion was calculated (c). 
Bars denote the mean ± SD. Albumin (N = 6), HES (N = 6), HES/Alb 
(N = 6) for galactose and wet-to-dry ratio; Albumin (N = 2-6), HES 
(N = 6), HES/Alb (N = 1-6) for lactate-to-pyruvate ratio. * p < 0.05;  
** p < 0.01; *** p < 0.001
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Effects of different colloid containing solutions 
on endothelial and epithelial barrier integrity
As surrogate parameter for endothelial and epithelial 
barrier dysfunction, we determined the translocation of 
vascularly applied FITC-dextran into the luminal com-
partment. Perfusion with HES significantly and time 
dependently increased the luminal FITC-dextran concen-
trations (p < 0.001 for t90–105, t105–120 and t120–135; 
Fig. 5), whereas the FITC-dextran translocation into the 
luminal compartment remained unchanged in the Alb 
and HES/Alb group (p > 0.05; Fig. 5). Compared to Alb 
perfusion significantly increased luminal FITC-dex-
tran concentration was observed during HES perfusion 
(p  <  0.01 for t75–90; p  <  0.001 for t90–105, t105–120 
and t120–135; Fig. 5). Replacing 1.5 % HES by 1.5 % Alb 
abrogated the HES associated translocation of vascularly 
applied FITC-dextran into the luminal compartment 
(p < 0.001 for t90–105, t105–120 and t120–135; Fig. 5). 
Concerning the FITC-dextran translocation into the 
luminal compartment, no statistically significant differ-
ences were detected between the Alb and HES/Alb group 
(p > 0.05; Fig. 5).
Claudin-3 is an integral membrane protein and a com-
ponent of tight junctions, which are forming continuous 
seals around cells, serving as a physical barrier to prevent 
solutes and water from passing freely through the para-
cellular space [23, 24]. Evaluation of the expression lev-
els of Claudin-3 protein in the intestinal tissue derived 
after perfusion did not reveal any differences between the 
groups (p > 0.05; Additional file 2: Figure 2).
Effects of different colloid containing solutions 
on phosphorylation of key signaling molecules
Compared to the perfusion with Alb, the phosphoryla-
tion of Erk1/2 and Akt was significantly increased in the 
HES/Alb group while Stat5 phosphorylation was reduced 
(p  <  0.001 for pErk1/2, p  <  0.01 for pAkt and pStat5; 
Fig. 6). In the HES group, only the phosphorylation pat-
terns of Akt and Stat5 were reduced (p < 0.05 for pAkt, 
p < 0.01 for pStat5; Fig. 6). Comparing the phosphoryla-
tion of Erk1/2, Akt and Stat5 between the HES perfusion 
and the HES/Alb perfusion groups showed a significant 
increase of Erk1/2 and Akt but not of Stat5 phosphoryl-
ation in the HES/Alb group (p  <  0.001 for pErk1/2 and 
pAkt, p > 0.05 for pStat5; Fig. 6).
Additional information about the measurements and 
raw data are also available in the Additional file 3.
























































































Fig. 4 Effects of different colloid containing solutions on vascular, 
lymphatic and luminal flow rates. Lymphatic (a) luminal (b) and 
vascular flow rates (c) were measured by quantifying the effluent 
volumes every 15 min (t45–60 = 1). Bars denote the mean ± SD. 
Albumin (N = 6), HES (N = 6), HES/Alb (N = 6). * p < 0.05; ** p < 0.01; 
*** p < 0.001



































Fig. 5 Effects of different colloid containing solutions on endothelial 
and epithelial barrier integrity. Luminal FITC-dextran concentra-
tions were measured by fluorometry every 15 min. Bars denote the 
mean ± SD. Albumin (N = 6), HES (N = 6), HES/Alb (N = 6).  
** p < 0.01; *** p < 0.001
Page 8 of 11Wong et al. J Transl Med  (2016) 14:60 
Discussion and conclusions
The application of HES for volume resuscitation is con-
troversially discussed and clinical studies have suggested 
adverse effects of HES substitution, leading to increased 
patient mortality [1, 4, 25]. The intestine is of high clini-
cal relevance and plays a crucial role in fluid homeostasis, 
sepsis and inflammation. Although some studies inves-
tigated the compatibility of colloids like Alb and HES in 
the perfused Langendorff heart [5] and kidney [6], infor-
mation about the effects of HES on intestinal function 
and barrier integrity is very scarce and intestinal effects 
of HES containing solutions have so far not been inves-
tigated in  vivo or using ex  vivo systems. Therefore, our 
work is the first study that describes in detail the influence 
of HES, HES/Alb and Alb on intestinal metabolism, cell 
damage, fluid distribution and barrier integrity employing 
an isolated perfused model of the mouse intestine.
We have recently shown that vascular perfusion with 
a clinically relevant concentration of 3  % HES [26, 27] 
impairs the endothelial and epithelial barrier integrity of 
the small intestine [19]. Interestingly, the results of ani-
mal studies suggested that addition of Alb to HES con-
taining solutions might be beneficial and may bear the 
potential to reduce adverse effects of HES [5, 11]. In the 
work presented here, we have therefore (i) reproduced 
and extended our previous ex  vivo studies and investi-
gated in more detail the physiological and cellular effects 
of a vascular perfusion with HES in the intestine, (ii) 
evaluated whether the addition of Alb to HES containing 
solutions is able to reduce the adverse effects of HES and 
(iii) screened for potential underlying mechanisms.
Effects of different colloids on histomorphology, cellular 
damage and metabolic function
Analyses of tissue damage were performed with intes-
tinal tissue that was obtained directly at the end 
of perfusion. A histological stability score which is 
based on the evaluation of epithelial integrity [21] was 
employed and revealed significantly increased histo-
morphological damage only in the HES perfusion group. 
Enterocyte coverage of the intestinal villi tips was almost 
completely lost in the HES group after 135  min perfu-
sion. In our previous study, enhanced sub-epithelial gaps 
and enlarged intercellular spaces were also evident in 
the stroma of most villi after HES perfusion, confirming 
our current results [19]. However, in our previous work 
[19], the histological stability score was not significantly 
different between the Alb and HES perfusion group. 
The observation of sub-epithelial gaps and enlarged 
intercellular spaces might be related to HES molecules 
that overcome the endothelial barrier and reside within 
the interstitial tissue compartment [28, 29]. As HES 
is osmotically active and able to bind large amounts of 
water [30], the fluid shift from the vascular to the inter-
stitial compartment might be increased, leading to 
the development of a transient interstitial edema. Sup-
plementation of the HES solution with Alb prevented 
all negative histomorphological effects of HES and 
resulted in a histological stability score similar to the one 
obtained after Alb perfusion. Although HES perfusion 
resulted in morphological damage, we did not detect 
any differences in the Caspase-3/7 activities between the 
groups. These findings suggest that HES induced cellular 
damage is not mediated via Caspase-3/7 associated path-
ways. However, several authors have shown that apopto-
sis in intestinal epithelial cells is detectable in the time 
frame between 1 and 24  h after the apoptosis inducing 
intervention was applied [31, 32] and we cannot exclude 
that the time frame of our experiment was too short to 
detect changes in Caspase-3/7 activity. Intestinal fatty 
acid binding protein (I-FABP) represents a commonly 
accepted marker protein for intestinal epithelial cell 
damage [33, 34]. The amounts of I-FABP in the lumi-
nal effluents were analysed by Western blotting and 
revealed that in the HES perfusion group most I-FABP 
is released within the first 30 min after the 60 min Alb 
equilibration phase. This observation suggests that cell 
damage already occurs shortly after switching the perfu-
sion buffer to 3 % HES, resulting in a release of I-FABP 
into the intestinal lumen. This is also substantiated by 
our above mentioned findings, that after 75 min of HES 
perfusion, the intestinal epithelium is severely damaged 
and the histoscore significantly reduced. The decline of 
I-FABP at later time points might be simply due to the 
fact that once the “pool” of cellular I-FABP is depleted, 
no new I-FABP protein will be released into the effluent. 
Moreover, as our model is based on a single perfusion 
method in which the perfusate is not re-circulated, a 
































Fig. 6 Effects of different colloid containing solutions on phospho-
rylation of key signaling molecules. Western blot analyses of Erk1/2, 
Akt and Stat5 phosphorylation in intestinal tissue lysates after perfu-
sion. Bars denote the mean ± SD. Albumin (N = 6), HES (N = 6), HES/
Alb (N = 6). *** p < 0.001; § p < 0.001 vs. Alb; $ p < 0.01 vs. Alb;  
# p < 0.05 vs. Alb
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Concerning the metabolic function of the perfused 
intestine, our results show a statistically significant 
reduction of lactose digestion and/or uptake of galac-
tose by the intestinal epithelium during HES perfusion. 
Adding Alb to the HES containing solution abrogated 
the adverse effects of HES and even increased galac-
tose uptake compared to the control perfusion with Alb 
alone. The latter, rather unexpected findings, suggests 
an increased metabolic activity of the intestine when a 
perfusion with HES and Alb is performed. However, our 
results are in accordance with data published by others 
which suggest that Alb in combination with HES can 
improve endothelial function [5, 11] and enhance tissue 
perfusion and oxygenation [35].
Effects of different colloids on endothelial and epithelial 
barrier function
Employing a previously established isolated perfused 
model of the mouse intestine [19], we describe a sig-
nificantly increased fluid shift from the intestinal vas-
culature into the luminal and lymphatic compartment 
of the small intestine during HES perfusion, indicative 
of a disruption of the endothelial and epithelial bar-
rier function. Our quantifications of vascularly applied 
FITC-dextran in the luminal effluents additionally con-
firm the above mentioned findings and strongly suggest 
adverse effects of HES on the epithelial and endothelial 
barrier. Besides the negative effects of HES on barrier 
integrity [5, 19, 36], a higher risk for renal replacement 
therapy and increased mortality after fluid resuscita-
tion with HES has been described [1, 4] and prompted 
the EMA Pharmacovigilance Risk Assessment Com-
mittee to instruct that HES solutions must no longer be 
used to treat patients with sepsis, burn injuries or criti-
cally ill patients (EMA/606303/2013). Interestingly, in 
our study, supplementing the HES containing solutions 
with Alb abrogated all adverse effects of HES on vascular, 
lymphatic and luminal fluid distribution as well as lumi-
nal FITC-dextran transfer, therefore improving endothe-
lial and epithelial barrier function. The different colloidal 
solutions employed in our study all revealed a similar 
colloid osmotic pressure, so that the favorable effects of 
Alb cannot be explained by osmotic pressure differences. 
Concerning the possible molecular mechanisms under-
lying the protective effects of Alb, recent studies sug-
gested an important role of the endothelial glycocalyx 
in the preservation of vascular integrity and regulation 
of endothelial permeability. Albumin contributes to the 
endothelial surface layer and stabilizes the glycocalyx by 
binding tightly to its components [37, 38]. As the glyco-
calyx also protects the endothelial cells from shear stress 
of blood flow [37] and mediates mechanotransduction 
[39], the absence of Alb may lead to an alteration and/or 
degradation of the glycocalyx. This process will probably 
be facilitated by the presence of bulky HES molecules, 
leading to increased barrier dysfunction. Other authors 
propose that Alb facilitates the solubility of the phospho-
lipid sphingosine-1-phosphate (S1P) in aqueous solutions 
[40] and that the stability of the glycocalyx depends on the 
presence the S1P and activation of the S1P receptor [40–
42]. S1P induced pathways, which involve Erk1/2 and Akt 
phosphorylation [43], act on the glycocalyx by suppress-
ing matrix metalloproteinase (MMP) activity, thereby 
protecting cell surface bound syndecan-1 molecules from 
cleavage by MMP-9 and MMP-13 [44]. Our preliminary 
results from syndecan-1 ELISA experiments also revealed 
an increased shedding and release of syndecan-1 from the 
glycocalyx in the HES perfusion but not in the Alb perfu-
sion group (data not shown). A recent study by Voyvodic 
et al. showed that syndecan-1 itself seems to be involved 
in intracellular signaling events. Shear stress induced 
phosphorylation of Akt was only observed in wild type 
endothelial cells, while syndecan-1 knockout cells were 
unable to elicit Akt mediated signaling [45]. Interestingly, 
our study also provides evidence for the involvement of 
pro-survival Akt and also Erk1/2 in Alb and HES medi-
ated signaling events. Compared to the HES perfusion, 
supplementation with Alb resulted in an increased phos-
phorylation of Akt and Erk1/2 but not Stat5. Whether or 
not Akt and Erk1/2 are directly involved in the adverse 
effects of HES and/or the protective functions of Alb 
needs to be established in further studies.
Limitations of the study
Based on its ex  vivo character, this study has several 
model related limitations which should be considered. 
(i) A vascular cell free perfusion was performed in our 
study. Therefore, the model does not account for possi-
ble effects of systemic immune cells and humoral factors 
on the described HES and Alb mediated mechanisms. (ii) 
Perfusion with colloid concentrations below 3 % leads to 
a metabolic and physiological instability of the ex  vivo 
model, as under these conditions colloid osmotic pres-
sure is considerably reduced. Therefore, in our experi-
mental setting vascular perfusion with 1.5  % Alb or 
1.5  % HES alone could not be performed and although 
our in vitro experiments suggest that HES in concentra-
tions of up to 3 % does not induce cell damage/apoptosis 
in intestinal epithelial cells, we cannot exclude the pos-
sibility that the positive effects of HES (1.5  %) plus Alb 
(1.5 %) on intestinal barrier function and metabolic activ-
ity are rather due to the reduction in HES concentration 
than to protective effects of Alb. (iii) While in  vivo, the 
vascularly applied HES will be diluted by the existent 
blood, distributed throughout the organism and the final 
HES concentration in the blood will be reached rather 
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slowly, in our model the final concentration of HES is 
established immediately without time delay. (iv) In-vivo 
HES is metabolized by various organs (e.g. liver, kidney) 
and has a vascular half-life of about 1.4–1.5 h [46]. These 
characteristics cannot be fully reflected in our single-
pass intestinal perfusion model in which the vascular 
HES concentration stays constant throughout the experi-
ment. However, the time frame of HES application and 
its vascular concentration correlate well with the clinical 
situation. (v) Possible effects mediated by the splanch-
nic nerves are not reflected in the perfused model of the 
small intestine, as the innervation is disrupted during 
organ preparation. However, the autonomously work-
ing enteric nervous system is still functioning in our 
model, as can be seen by the regular peristaltic move-
ments of the perfused intestine [19]. To eliminate some 
of the model related deficiencies, in further studies the 
isolated perfused mouse small intestinal model could 
also be combined with a vascular whole blood perfusion. 
This approach will give deeper insights into the potential 
interactions of HES molecules with systemic immune 
cells as well as the humoral immune system and will help 
to better reflect the clinical scenario of fluid supplemen-
tation in our ex vivo model.
Conclusion
Taken together, employing an isolated perfused model of 
the mouse intestine, we show that Alb supplementation 
abrogates the adverse effects of HES on barrier integ-
rity and metabolic function in the intestine and that the 
underlying mechanism may involve phosphorylation of 
Erk1/2 and Akt. Our data suggest that adding Alb to HES 
containing solutions could have the potential to reduce 
the adverse effects of HES and improve its suitability in 
the clinic.
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(N = 3). ** p < 0.01; *** p < 0.001.
Additional file 2: Figure 2. Effects of different colloid containing solu-
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